Actively Recruiting
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2026-02-06
3596
Participants Needed
6
Research Sites
414 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.
CONDITIONS
Official Title
Further Lipid-Lowering With PCSK9 Inhibitors for Cardiovascular Outcomes in High-Risk Coronary Plaques Assessed by CT Angiography
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Patients with at least one target lesion showing CCTA-detected plaque with degree of stenosis 50% or more or plaque burden 70% or more
- Target lesion has at least two high-risk plaque features: low-attenuation plaque, positive remodeling, napkin-ring sign, or spotty calcium
- Target lesion located in proximal or mid segment of left anterior descending artery, left circumflex artery, or right coronary artery
- Able to understand study risks, benefits, and alternatives and provide written informed consent
You will not qualify if you...
- Target lesions that have undergone or are planned for revascularization
- Patients with acute coronary syndrome
- New York Heart Association class III or IV heart failure or left ventricular ejection fraction less than 30%
- Uncontrolled or recurrent ventricular tachycardia
- Homozygous familial hypercholesterolemia
- Active liver disease or hepatic dysfunction
- Failed coronary CT angiography plaque analysis
- Non-cardiac conditions with life expectancy less than 2 years
- Pregnant or breastfeeding women
- Known allergy or contraindication to statins or PCSK9 inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Hangzhou, Zhejiang, China
Actively Recruiting
2
Hangzhou Linping First People's Hospital
Hangzhou, China
Actively Recruiting
3
The Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, China
Actively Recruiting
4
Zhejiang Hospital
Hangzhou, China
Actively Recruiting
5
Jinhua Central Hospital
Jinhua, China
Actively Recruiting
6
Seoul National University Hospital
Seoul, South Korea
Not Yet Recruiting
Research Team
X
Xinyang Hu
CONTACT
J
Jian'an Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here